Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00963872 · ClinicalTrials.gov registry record · Phase 1
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
A Phase 1 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT00963872 is a Phase 1 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 31 participants.
The verdict
NCT00963872, a Phase 1 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). PURPOSE: This phase I trial is studying the safety of donor umbilical cord blood transplant after fludarabine phosphate, cyclophosphamide, and total-body irradiation in treating patients with high-risk hematologic cancer (now closed). The Phase II part of this trial is studying whether priming one of two UCB units with C3a facilitates engraftment of the treated unit.
Interventions
- RADIATION Total body irradiation
- DRUG cyclophosphamide
- DRUG fludarabine phosphate
- BIOLOGICAL Umbilical cord blood unit with C3a fragment
- BIOLOGICAL Unmanipulated UCB Unit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2010-03 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00963872
The ClinicalTrials.gov registry entry for NCT00963872 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Total body irradiation is the first listed.
NCT00963872 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00963872 about?
NCT00963872 is a clinical study titled "Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer". RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cel...
What is the current status of trial NCT00963872?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2010-03. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00963872?
The interventions under investigation include: Total body irradiation (RADIATION), cyclophosphamide (DRUG), fludarabine phosphate (DRUG), Umbilical cord blood unit with C3a fragment (BIOLOGICAL), Unmanipulated UCB Unit (BIOLOGICAL).
Who is sponsoring clinical trial NCT00963872?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.